

## Supplementary material

Table 1: amount of residual disease.

		<b>2007-2016</b> N = 75	<b>2017-2021</b> N = 204
<b>Amount of residual disease for patients with residual disease – no (%)</b>			
	CC1	11 (78.6%)	9 (50.0%)
	CC2	2 (14.3%)	1 (5.6%)
	CC3	0 (0.0%)	8 (44.4%)
	Missing	1 (7.1%)	0 (0.0%)

Table 2: repartition of the patient between primary debulking surgery and Neoadjuvant Chemotherapy (NACT), and number of cycles before debulking in the two cohorts

		<b>2007-2016</b> N = 75	<b>2017-2021</b> N = 204
<b>Debulking Surgery – n (%)</b>			
	Without NACT	8 (10.7)	93 (45.6)
	With NACT	67 (89.3)	111 (54.4)
	After 3 cycles NACT	8 (11.9)	51 (45.9)
	After 4 cycles NACT	14 (20.9)	13 (11.7)
	After 5 cycles NACT	1 (1.4)	2 (1.8)
	After 6 cycles NACT	44 (65.7)	45 (40.5)

Table 3: Detail of the post operative complications in the two cohorts


Type of complications	Cohort 2007-2016 N=14	Cohort 2017-2021 N=63
Urinary infection	4 (28.6%)	15 (23.8%)
Anemia	7 (50.0%)	26 (41.3%)
Kidney failure	0 (0.0%)	2 (3.2%)
Veinous phlebitis (exclude upper membre phlebitis)	0 (0.0%)	4 (6.3%)
Pulmonary Thrombo-embolism	0 (0.0%)	4 (6.3%)
Secondary hemorrhage	0 (0.0%)	4 (6.3%)
Pneumothorax	0 (0.0%)	3 (4.8%)
Fecalis peritonitis	0 (0.0%)	7 (11.1%)
Chylorrhea	1 (7.1%)	4 (6.3%)
Lymphorrhoea	0 (0.0%)	3 (4.8%)

Duodenum leakage	0 (0.0%)	1 (1.6%)
Pancreatic fistula	0 (0.0%)	1 (1.6%)
Abdominal wall complication (eviseration, necrosis,..)	1 (7.1%)	7 (11.1%)
Other	2 (14.3%)	33 (52.4%)
Gastroparesis/Postop ileus	0 (0.0%)	9 (14.3%)
Pyrexia	0 (0.0%)	3 (4.8%)
S. aureus sepsis	0 (0.0%)	2 (3.2%)
Cardiac arrhythmia	1 (7.1%)	2 (3.2%)

Table 4. Details of the surgical procedures performed in each cohort


Procedure	Cohort 2007-2016 N=75	Cohort 2017-2021 N=204	p-value
Hysterectomy	65 (86.7%)	153 (75.0%)	0.037*
Bilateral salpingoophorectomy	71 (94.7%)	149 (73.0%)	<0.001 *
Pelvic peritonectomy	30 (40.0%)	167 (81.9%)	<0.001 *
Complete omentectomy (untill stomach)	72 (96.0%)	176 (86.3%)	0.022 *
Parietal peritonectomy	11 (14.7%)	87 (42.6%)	<0.001 *
Parietocolic peritonectomy	22 (29.3%)	93 (45.6%)	0.014 *
Right diaphragm stripping	17 (22.7%)	107 (52.5%)	<0.001 *
Morisson pouch peritonectomy	17 (22.7%)	95 (46.6%)	<0.001 *
Left diaphragm stripping	4 (5.3%)	40 (19.6%)	0.004 *
Small omentum removal	5 (6.7%)	38 (18.6%)	0.014 *
Porta hepatitis surgery	3 (4.0%)	18 (8.8%)	0.176
Cholecystectomy	3 (4.0%)	17 (8.3%)	0.214
Splenectomy	2 (2.7%)	29 (14.2%)	0.007 *
Small bowell resection	1 (1.3%)	11 (5.4%)	0.191
Small bowel and mesenterium fulguration	9 (12.0%)	45 (22.1%)	0.059
Left large bowel resection	17 (22.7%)	43 (21.1%)	0.870
Right large bowel resection	3 (4.0%)	8 (3.9%)	0.999
Pelvis lymphadenectomy	50 (66.7%)	61 (29.9%)	<0.001 *
Lombo-aortic lymphadenectomy	34 (45.3%)	66 (32.4%)	0.045 *
Diaphragmatic resection	1 (1.3%)	23 (11.3%)	0.009 *
Mediastin node removal	0 (0.0%)	2 (1.0%)	0.999
Other	36 (48.0%)	64 (31.4%)	0.010 *
Appendicectomy	30 (40.0%)	35 (17.2%)	<0.001 *
Hepatectomy	1 (1.3%)	4 (2.0%)	0.999
Protective illeo-Stoma	0 (0.0%)	3 (1.5%)	0.566

Figure 1 – Disease-free survival of patients without maintenance therapy.



	<b>2007-2016</b> <b>N = 68</b>	<b>2017-2021</b> <b>N = 157</b>	<b>p-value</b>
Kaplan Meier of disease free survival (months)			
Median	16.5	27.1	<0,001
Confidence Interval 95%	(13.1 – 21.0)	(21.5 – 33.2)	

Figure 2- Disease-free survival of patients that were completely resected (CC0)



	2007-2016 N = 61	2017-2021 N = 185	p-value
Kaplan Meier disease free survival (months)			
Median	18.7	28.1	<0,001
Confidence Interval 95%	(13.5 – 23.0)	(23.7 – 33.8)	

Table 5. Uni- and multivariate analysis of Disease Free Survival using Cox proportional hazard ratio model. Centralization is significantly associated with a better Disease Free Survival.

UNI AND MULTIVARIATE REGRESSION ANALYSES ON RECURRENCE-FREE SURVIVAL  
(ALL PATIENTS)

Factor	Value	Univariate			Multivariate		
		p-value	Hazard-Ratio	HR 95CI	p-value	Hazard-Ratio	HR 95CI
Amount of residual	CC2-CC3	0.002	3.21	(1.552 - 6.631)			
CA_125_initial		0.643	1.00	(1.000 - 1.000)			
Cohort	2017-2021	<0.001	0.56	(0.399 - 0.774)	0.427	0.80	(0.455 - 1.395)
Grade	III	0.006	2.71	(1.326 - 5.556)	0.092	2.49	(0.861 - 7.183)
HIPEC	Yes	0.352	0.51	(0.125 - 2.093)			
Initial_ascite_volum	0-500ml	0.665	1.15	(0.619 - 2.122)			
	11 - 31	0.131	1.66	(0.860 - 3.217)			
	500ml - 11	0.316	1.52	(0.672 - 3.420)			
	> 31	0.128	1.66	(0.864 - 3.196)			
Initial_ascites	Yes	0.234	1.41	(0.803 - 2.464)			
Mutation_BRCA	Yes	0.010	0.42	(0.216 - 0.810)	0.011	0.38	(0.183 - 0.799)
Necadj_chemotherapy	Yes	<0.001	2.14	(1.430 - 3.209)			
PARP_inhibitor	Yes	0.935	1.02	(0.594 - 1.761)			
Residual_disease	Yes	<0.001	2.35	(1.521 - 3.638)	0.004	3.16	(1.447 - 6.909)
age		<0.001	1.03	(1.017 - 1.042)	0.045	1.02	(1.000 - 1.047)
figo	IV	0.265	1.23	(0.857 - 1.752)			

